High-dose myeloablative chemotherapy supported by peripheral blood progenitor cell (PBPC) transplant is rapidly replacing bone marrow transplant to treat a number of chemosensitive cancers. Numerous investigators have studied the relationship of CD34 + cell dose and engraftment kinetics in an effort to help define minimum and optimum target stem cell doses. A number of studies suggest that reinfusion of у5 × 10 6 CD34
High-dose chemotherapy (HDC) supported by peripheral blood progenitor cell (PBPC) transplant is being increasingly used to treat a number of chemosensitive cancers such as breast cancer, lymphoma, and multiple myeloma. PBPC transplant is rapidly replacing bone marrow transplant, not only because of decreased risks and greater convenience, but because transplant with PBPCs results in more rapid platelet and neutrophil recovery. [1] [2] [3] The dose of stem cells delivered to the patient has been shown to have a critical impact on hematopoietic recovery. 4 A number of studies suggest that for most patients receiving PBPC, reinfusion of у5 × 10 6 CD34 + cells/kg results in prompt and durable platelet engraftment. Patients receiving Ͻ1 to 2 × 10 6
CD34
+ cells/kg are at risk for delayed platelet recovery or engraftment failure. 3, [5] [6] [7] [8] One emphasis of clinical studies has been to identify mobilization regimens that maximize stem cell collection. Higher stem cell yields collected in fewer aphereses will not only hasten hematopoietic reconstitution, but will also decrease the morbidity and expense associated with repeated collection procedures. In addition, greater stem Correspondence: Dr EJ Shpall, University Hospital -BMT Program, University of Colorado, Box B190, 4200 E. 9th Ave, Denver, Colorado 80262, USA cell yields will make possible, for greater numbers of patients, the manipulation of stem cell grafts in order to purge, select, or expand specific cell populations, or use progenitor cells in gene therapy.
PBPC mobilization regimens frequently employ filgrastim (r-metHufilgrastim) to increase the number of hematopoietic progenitors in peripheral blood. However, when using filgrastim alone, 20% of patients require у4 aphereses to reach 1 × 10 6 CD34 + cell/kg, and 60% of patients require у4 aphereses to reach 5 × 10 6 CD34 + cells/kg. 4 One strategy to improve PBPC yields is to use filgrastim in combination with chemotherapy; another is to use filgrastim together with other hematopoietic growth factors, including recombinant human stem cell factor, 4,9-11 recombinant Mpl ligands, 12, 13 flt-3 ligand, 14 or interleukin-3 receptor ligands. 15 The most extensively studied combination is filgrastim and SCF, which has been shown to enhance PBPC mobilization both with and without chemotherapy. 4, 10, 11 SCF is a pleiotropic growth factor with a broad range of activity in hematopoietic cells. In early progenitor cells, SCF promotes the survival of stem cells and proliferation of primitive undifferentiated progenitor cell populations. In late progenitor cells, SCF acts in concert with other growth factors to stimulate colony formation of erythroid-and myeloid-committed progenitor cells. Unlike most committed cells of the hematopoietic lineage, mast cells retain responsiveness to SCF. 16 A key characteristic of SCF is its ability to synergize with other growth factors. In vitro studies show that while recombinant SCF has little colony-stimulating activity of its own, colony formation is increased when SCF is added to other hematopoietic growth factors. [16] [17] [18] Synergism of SCF with other factors also occurs in vivo. In preclinical animal models using rats, dogs, and baboons, SCF in combination with filgrastim increased PBPC mobilization, compared to filgrastim alone. 19 Reinfusion of increased numbers of PBPCs following myeloablation resulted in more rapid engraftment. 19 These animal studies provided the rationale for PBPC mobilization trials utilizing SCF and filgrastim in humans.
In a recent phase 2 clinical trial of 212 breast cancer patients receiving identical HDC and supportive engraftment, CD34
+ cell numbers were used to construct a Cox proportional hazards model (Figure 1) .
The model predicts that patients receiving an infusion of 5 × 10 6 CD34 + cells/kg will have an 85% probability of platelet engraftment to 20 × 10 9 /l by day 14 post transplant, and a very low incidence of delayed platelet recovery beyond 28 days. The model predicts that the infusion of Ͻ5 × 10 6 CD34 + cells/kg will be associated with a lower probability of rapid platelet engraftment. 4 Based on the above model, we conducted a phase 3 clinical trial to com- pare mobilization of PBPCs with SCF plus filgrastim or filgrastim alone. This study was designed specifically to determine the number of apheresis procedures required to obtain 5 × 10 6 CD34 + cells/kg.
Trial parameters
This phase 3 trial was a multicenter (14 US sites), randomized, open-label study in 203 previously treated breast cancer patients. Patients had high-risk stage II, III, or IV breast cancer and had received a median of five cycles of prior chemotherapy (Table 1) . The median patient age was 46 years. Upon study enrollment, patients were randomized to one of two treatment groups, as shown in the study schema ( Figure 2 ). One hundred and three patients received filgrastim alone (10 g/kg/day), and 100 received the cytokine combination (SCF 20 g/kg/day and filgrastim 10 g/kg/day). Cytokines were administered daily by subcutaneous (s.c.) injection starting on day 1 and continuing up to 9 days. Because of mast-cell-related side effects noted in a phase 1 clinical trial, 20 the study was limited to patients without a history of serious allergic disorder, including asthma, angioedema, or anaphylaxis. All patients received a premedication regimen consisting of H 1 and H 2 antihistamines, an inhaled bronchodilator, and pseudoephedrine. Apheresis began on the fifth day of cytokine administration and continued daily until the target number of PBPCs had been collected or a maximum of five collections was performed. A central laboratory determined CD34
+ cell content concentration from apheresis samples. Following PBPC collection, and after a rest period of 2 to 10 days, patients with a minimum number of PBPCs collected (at least 1 × 1 day). All previously collected PBPCs were reinfused 2 days following the last dose of chemotherapy. Following PBPC infusion, all patients received filgrastim 10 g/kg/day administered daily until neutrophil recovery was achieved. The analysis was based on an intent-to-treat and evaluable patient cohort strategy. The endpoints of the study were to: (1) determine the number of aphereses required to reach a target of 5 × 10 6 CD34 + cells/kg; (2) evaluate engraftment as measured by the number of days until neutrophil engraftment (ANC у0.5 × 10 9 /l) and platelet engraftment (у20 × 10 9 /l); and (3) determine the safety profile of SCF.
Key results and conclusions
The key results and conclusions from the phase 3 study were: (1) SCF is safe and effective for the mobilization of PBPCs in combination with filgrastim; (2) the number of aphereses required to collect an optimal target number of PBPCs was reduced; and (3) the proportion of patients able to mobilize optimal numbers of PBPCs was increased.
Adverse events
In general, SCF plus filgrastim was well tolerated when administered s.c. at the dose of 20 g/kg/day for up to 9 consecutive days. Adverse events generally were mild to moderate in severity for both treatment groups. The most frequently reported adverse event in the SCF plus filgrastim group, which occurred in 92% of patients, was a local injection-site reaction. The incidence of adverse events occurring at у5% difference between treatment groups during the collection phase is shown in Figure 3 .
There were no fatal or life-threatening events. Severe events were reported in 17% of the SCF plus filgrastim group and in 12% of patients treated with filgrastim alone. Five patients experienced serious side effects that were possibly attributable to SCF; three patients experienced systemic allergic-like reactions of the type reported previously. 20 All symptoms resolved once SCF was discontinued and antihistamines and/or steroids were administered.
Increased CD34
+ cell yields Increased CD34 + cell yields were consistently achieved with the combination of SCF plus filgrastim (Figure 4 ). This increase was statistically significant on apheresis days 3, 4, and 5 (P Ͻ 0.01). The increase in CD34
+ cells was sustained throughout the apheresis period to a greater degree in patients receiving the cytokine combination. A greater proportion of patients reached the target PBPC yield (within 5 days of apheresis) in the SCF plus filgrastim group (67%) compared to the filgrastim-alone group (48%). These results were statistically significant (P Ͻ 0.05).
Decreased number of apheresis procedures
Patients in the combination SCF plus filgrastim group reached the target number of PBPCs (у5 × 10 6 CD34 + cells/kg) with a median of four apheresis collection procedures, whereas patients in the filgrastim-alone group required a median of у6 apheresis procedures. These results were statistically significant (P Ͻ 0.05). Therefore, patients mobilized with the combination required at least two fewer apheresis procedures for collection of the target PBPC number compared to patients mobilized with filgrastim alone. Reduction in the number of apheresis procedures should improve patient convenience, reduce morbidity associated with apheresis procedures, and reduce costs associated with PBPCs transplant procedures.
Hematopoietic recovery
Hematopoietic recovery following HDC and infusion of the collected PBPCs was similar for the two groups ( Figure 5 ). Median days to neutrophil recovery (ANC у0.5 × 10 9 /l) was 10 days in the SCF plus filgrastim group and 9 days in the filgrastim-alone group. Median days to transfusionindependent platelet recovery (PLT у20 × 10 9 /l) was 11 days for both groups.
These similar engraftment results were expected, since the patients were all apheresed to the same target PBPC yield. Infusion of an optimal number of PBPCs assured rapid, sustained, and predictable hematopoietic engraftment, reduced morbidity post transplant, reduced engraftment outliers, and reduced hospital costs.
Mobilization or engraftment failures
The proportion of patients who were either unable to mobilize a minimum number of PBPCs (1 × 10 6 CD34 + cells/kg), or experienced delayed platelet recovery (у28 days), was lower in the group receiving the combination of SCF plus filgrastim for mobilization as compared to patients receiving filgrastim alone ( Figure 6 ). In the cytokine combination group, 3.5% of patients experienced mobilization or platelet engraftment failure compared to 7.4% of patients in the filgrastim-alone group. Because the percentage of patients reaching minimal numbers of CD34
+ cells was increased with the combination of SCF plus filgrastim, more patients were able to undergo HDC with PBPC transplant.
Tumor cell contamination
Tumor cell contamination was comprehensively studied and found to be very low (Table 2 ). Tumor cells were detected in the bone marrow, peripheral blood, and/or PBPCs of 21 patients. Nine of the patients receiving SCF plus filgrastim were found to have tumor cell contamination of some of the specimens, while 12 patients receiving filgrastim alone were found to have contamination.
Ten of the patients had clinical stage II-III disease while 11 had clinical stage IV disease. There was no statistically significant difference in the rate of PBPC contamination between patients receiving the combination treatment compared to those receiving filgrastim alone. Additionally, bone marrow specimens were compared to the apheresis products. There was no evidence of tumor cell mobilization from the marrow into the blood. Results may have been unusually low since a prerequisite for study entry was Ͻ10% marrow involvement.
Discussion
Several investigators have shown an increased overall response rate in breast cancer patients with the use of HDC. 21 The percent of patients achieving complete remission and relapse-free survival also has been shown to increase with HDC. 22, 23 Myeloablative chemotherapy, however, requires stem cell support for rapid hematopoietic recovery. These stem cells can be harvested from peripheral blood following mobilization through PBPC transplantation.
Stem cell dose, enumerated by identifying cells that S17 Table 2 Hematopoietic fractions containing tumor cells express the CD34 + cell surface antigen, can be a useful predictor of post transplant hematopoietic recovery. 24 Numerous investigators have studied the relationship of CD34 + cell dose and engraftment kinetics in an effort to help define minimum and optimum target stem cell doses. Cell doses of Ͻ1 × 10 6 CD34 + cells/kg have been associated with a higher risk of delayed engraftment of platelets in a large proportion of patients, 25 while doses of 2 to 2.5 × 10 6 CD34 + cells/kg generally have been associated with acceptable engraftment kinetics for most patients. 5, [26] [27] [28] [29] [30] [31] [32] However, at CD34 + cell doses у5 × 10 6 cells/kg, rapid platelet engraftment ensued for all but a few patients. 3, 4, 6, 7, 33, 34 Thus, the difference between engraftment kinetics for doses of 2 to 2. + cells/kg were required to assure rapid recovery in patients with a history of longer chemotherapy exposure. However, in general, it is not possible to accurately predict who will require stem cell doses у5 × 10 6 CD34 + cells/kg. Consequently, this dose should be considered optimal to ensure that all patients are given an adequate opportunity for rapid recovery.
Specimen
Use of stem cell doses у5 × 10 6 CD34 + cells/kg is not only associated with a more rapid hematological recovery but also with lower costs due to fewer transfusion requirements, shorter hospital stays, less antibiotic use, and reduced growth factor support. 4, 35 Mobilization of stem cells can be accomplished through use of chemotherapy alone, colony-stimulating factors, or a combination of the two. However, chemotherapy, when used alone as a mobilization regimen, has been associated with higher transfusion requirements as well as an increased risk of infection. 36 Mobilization regimens that employ the cytokine combination of SCF and G-CSF have been shown to be more effective in increasing progenitor cell yields in cancer patients, including hard-to-mobilize patients. 4, 9, 37 In this study, as well as the study by Glaspy et al, 4 the cytokine combination has also resulted in a reduction in the number of aphereses required. In this study, the median number of aphereses to reach the target cell yield was four for patients receiving SCF plus filgrastim, whereas patients receiving filgrastim alone required a median of six or more aphereses to reach the target yield. There are advantages to reducing the number of aphereses besides the obvious one of cost reduction. Multiple aphereses are associated with morbidity including catheterrelated infection, thrombosis, electrolyte imbalances, hypocalcemia, hypotension, and in at least one report, risk of relapse from the delay of prolonged aphereses. 36 It has also been shown that mobilization of progenitor cells is more sustained over time when the combination of SCF plus filgrastim is used as compared to filgrastim alone. The rate of decline in cell yield across days of apheresis was markedly lower in the combination group in this study. This indicates that the CD34 + cell yield was sustained for a longer period of time. Sustaining cell yield may limit the need for repeat apheresis procedures. It may also allow flexibility in scheduling so as to optimize transplant center resources.
The SCF plus filgrastim combination may play a significant role in future treatment strategies, including ex vivo expansion. Preliminary preclinical data indicate that when peripheral blood is mobilized, CD34 + -selected and then cultured ex vivo with cytokines for 10 days, expansion of cells mobilized with SCF plus filgrastim is greater compared with filgrastim alone. Ex vivo expansion should be studied clinically to determine if engraftment can be hastened still further. Initial infusion of expanded cells may serve as a useful supplement to subsequent infusion of unmanipulated CD34 + cells. Other future strategies could include tumor cell purging.
In conclusion, data from numerous studies indicate that while 1 to 2 × 10 6 CD34 + cells/kg can be considered an adequate graft, doses Ͼ5 × 10 6 CD34 + cells/kg are associated with more rapid engraftment and a lower probability of graft failure. The combination of SCF plus filgrastim allows for an increased proportion of breast cancer patients to reach this target yield compared with filgrastim alone. Also, SCF plus filgrastim provided a more sustained increase in CD34
+ cell yields when compared to filgrastim alone. There was a median reduction of at least three aphereses for those patients receiving combination therapy. The cytokine combination was generally well tolerated with no life-threatening toxicity observed when used with premedication. The SCF plus filgrastim combination may substantially impact morbidity as well as diminish costs associated with PBPC transplantation.
